Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.

Molecular cancer research : MCR - 1 Aug 2016

Keller James, Nimnual Anjaruwee S, Varghese Mathew S, VanHeyst Kristen A, Hayman Michael J, Chan Edward L

Abstract excerpt

UNLABELLED: EGFR is a popular therapeutic target for many cancers. EGFR inhibitors have been tested in children with refractory neuroblastoma. Interestingly, partial response or stable disease was observed in a few neuroblastoma patients. As EGFR mutations are biomarkers for response to anti-EGFR drugs, primary neuroblastoma tumors and cell lines were screened for mutations. A novel EGFR extracellular domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Mutation

Share to Neuroblastoma

Share to Phosphorylation

Share to Signal Transduction

Share to Transfection

Source

Open in PubMed Open full text

Identifiers

PMID: 27216155
DOI: 10.1158/1541-7786.MCR-15-0477
PMCID: PMC4987210

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.PMID 27216155Read ↗

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastomaSemantic proximity Read ↗

Mutant epidermal growth factor receptors as targets for cancer therapy.Semantic proximity Read ↗

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.Semantic proximity Read ↗

Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.Semantic proximity Read ↗

EGFR mutations and abnormal trafficking in cancers.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.Semantic proximity Read ↗

Identification of an Exon 4-Deletion Variant of Epidermal Growth Factor Receptor with Increased Metastasis-Promoting CapacitySemantic proximity Read ↗

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targetingSemantic proximity Read ↗

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.Semantic proximity Read ↗

Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.Semantic proximity Read ↗

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.Semantic proximity Read ↗

Activating mutations in ALK provide a therapeutic target in neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.